Daiichi Sankyo Company, Limited

4568.T
Drug Manufacturers - General
2026/07/31 Updated
Market Cap: $33.2B (¥5.3T)
Stock Price: $18.23 (¥2,889)
Exchange Rate: 1 USD = ¥158.48

Daiichi Sankyo Q1 FY2027 Earnings|Sales of ¥574.7 billion (+21.1% YoY)

In the first quarter of FY2027, Daiichi Sankyo achieved sales of ¥574.7 billion (up 21.1% YoY), operating profit of ¥85.1 billion (down 12.0%), and net income attributable to owners of the parent of ¥68.6 billion (down 19.7%). The strong start was driven by sales growth and favorable exchange rates, although net income declined.

Importance:
Page Updated: July 31, 2026
IR Disclosure Date: July 31, 2026

Key Figures

  • Revenue: ¥574.7 billion (up 21.1% YoY)
  • Operating profit: ¥85.1 billion (down 12.0%)
  • Net income attributable to owners of the parent: ¥68.6 billion (down 19.7%)

AI要約

Overview of Performance

In the first quarter of FY2027, Daiichi Sankyo achieved a substantial increase in revenue to ¥574.7 billion (up 21.1% YoY). This was mainly driven by growth in Enherts and Datravoy products, as well as favorable exchange rates due to yen depreciation. Core operating profit was ¥107.3 billion (up 6.2%), while operating profit decreased to ¥85.1 billion (down 12.0%), and net income attributable to owners of the parent fell to ¥68.6 billion (down 19.7%). Increased R&D and selling, general, and administrative expenses also contributed to the decline.

Forecasts and Shareholder Returns

The full-year sales forecast for FY2027 is ¥2.34 trillion (up 10.2%), with a planned dividend increase of ¥50 to an annual total of ¥100. The company aims to continue investing in R&D while enhancing shareholder returns through active share buybacks and dividend policies, emphasizing sustainable long-term growth.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Daiichi Sankyo Company, Limited

Company overview · Stock price · Financial data · All IR

View company page →